PGT-A With Donor Eggs: What the Research Shows and Who It’s Right For

If you’re planning a donor egg IVF cycle, there’s a good chance Preimplantation Genetic Testing for Aneuploidy (PGT-A) has come up. It screens embryos for chromosomal abnormalities before transfer, with the goal of improving implantation rates and reducing miscarriage risk. For many intended parents, the idea of having that extra layer of information before a transfer feels reassuring.

Here’s what most people don’t know going in: PGT-A with donor eggs operates differently than PGT-A with your own eggs. The research on it is more nuanced, the benefits depend heavily on your specific situation, and the decision deserves a real conversation with your care team — not a default yes or no. At Lucina Egg Bank, we offer a PGT-A Guarantee program because we know it genuinely matters for some intended parents. We also think you should understand exactly how it works before deciding.

This article covers what the evidence actually shows about PGT-A in donor egg cycles, who it benefits most, what to think through before adding it to your plan, and how Lucina’s guarantee program is structured if you choose to move forward with it.

What PGT-A Is and How It Works

PGT-A screens embryos for chromosomal abnormalities, specifically aneuploidies: embryos with the wrong number of chromosomes. A normal human embryo has 46 chromosomes arranged in 23 pairs. Aneuploid embryos have too many or too few. Most fail to implant, miscarry early, or result in conditions like Down syndrome.

The test works by biopsying a few cells from a day-5 embryo (a blastocyst, the stage of development that occurs around five days after fertilization) before transfer. Those cells are analyzed for chromosomal count. Embryos flagged as euploid (normal) move forward; aneuploid embryos are set aside or discarded.

The appeal is understandable. Knowing which embryos are chromosomally normal before transfer feels like it should improve outcomes. For patients using their own eggs, particularly women in their late 30s and 40s where aneuploidy rates rise steeply with age, the data generally supports that logic. For a 40-year-old using her own eggs, the rate of chromosomally abnormal embryos can exceed 70%. Screening meaningfully changes what’s available to transfer.

Donor egg cycles start from a different baseline. Donors are young — at Lucina, all donors are ages 19–31. Aneuploidy rates are significantly lower in that age group. That doesn’t make PGT-A irrelevant in donor cycles. It means the calculus is different, and the decision depends more on your individual circumstances than on a general rule.

What the Research Says About PGT-A in Donor Egg Cycles

Two key evidence sources frame this conversation: ASRM’s 2024 committee opinion and a large registry-based analysis of real-world donor cycles. Both are worth understanding clearly, because the nuance in both is often lost in how PGT-A gets presented to patients.

ASRM’s 2024 Position

The American Society for Reproductive Medicine’s (ASRM) 2024 Committee Opinion on PGT-A reviewed the full body of evidence across IVF populations. For donor egg cycles specifically, it concluded that “the totality of evidence argues against the routine use of PGT-A in donor egg cycles.”

The operative word is routine. ASRM is not saying PGT-A is inappropriate across the board. It’s saying the evidence doesn’t support applying it by default to every donor egg cycle — which is a meaningful distinction from saying it shouldn’t be used at all. Plenty of reproductive endocrinologists recommend it for specific patients with specific clinical histories, and that recommendation can be well-founded.

The SART CORS Analysis: 18,562 Donor Cycles

A large analysis using SART’s Clinic Outcome Reporting System (CORS) database examined 18,562 donor egg IVF cycles. After multivariable adjustment, PGT-A was associated with lower live birth rates in fresh donor oocyte cycles and showed no statistically significant improvement in live birth rates for frozen-thawed donor cycles.

There was one consistent finding that looks like a genuine benefit: cycles with PGT-A showed a higher rate of single embryo transfer (SET), which reduced multiple pregnancies. For intended parents who prioritize a singleton pregnancy, that’s a real consideration worth weighing.

A separate 2020 study in Human Reproduction examined donor-oocyte recipients and found PGT-A did not improve the chance of live birth in the first transfer cycle. These findings inform the ASRM position, but they represent population-level averages — not individual clinical predictions.

Why Donor Egg Cycles Are a Different Conversation

Understanding why PGT-A plays a different role in donor cycles helps you ask better questions when you’re making this decision. A few factors explain the difference.

• Donor age changes the baseline. Chromosomal abnormality rates in embryos are closely tied to the age of the egg at retrieval. Young donors in the 19–31 range produce eggs with a lower aneuploidy rate than patients in their late 30s or 40s. The pool of chromosomally normal embryos is already larger relative to older-egg IVF cycles, which reduces the proportional benefit of screening.
• Donors are already medically screened. Before a single egg enters Lucina’s inventory, donors undergo extensive evaluation: genetic carrier screening, complete medical and family health history review, psychological assessment, and compliance with FDA and ASRM standards. That upstream screening addresses many of the genetic risk factors PGT-A is designed to catch downstream. Read more about what egg donor screening involves.
• Embryo pool size matters. A donor egg cohort typically contains 6–8 eggs. After thaw, fertilization, and development to blastocyst, you may have 2–4 embryos to work with. PGT-A removes any flagged embryos from that pool. If the test flags an embryo that would have implanted successfully, that’s a real cost. This is especially worth thinking through when your cohort is on the smaller side.
• Mosaic results add complexity. Some embryos come back as mosaic: a mix of chromosomally normal and abnormal cells. These fall into a gray zone where guidance varies by clinic, and some mosaic embryos do result in healthy pregnancies. ASRM acknowledges that existing data cannot support firm recommendations on how to handle mosaic results. If PGT-A is part of your plan, it’s worth asking your clinic upfront what their approach to mosaics is.

Who Benefits Most From PGT-A in a Donor Egg Cycle

The research doesn’t support applying PGT-A by default to every donor egg cycle — but there are specific situations where the added information genuinely serves the intended parent. Your reproductive endocrinologist is the right person to assess whether your situation is one of them. Here’s what those situations typically look like.

What Drives Outcomes in Donor Egg IVF

PGT-A is one variable in a cycle with many. Understanding what else drives outcomes helps you put this decision in context and have a more complete conversation with your care team.

• Egg quality at vitrification. Post-thaw survival rate reflects the egg bank’s vitrification protocols and lab quality. Lucina’s 2022 post-thaw survival rate is 92.2%. No national public benchmark for this metric exists in SART’s published data, which makes that figure meaningful when comparing banks. Learn more about frozen donor egg benefits and how vitrification affects egg quality.
• Fertilization rates. After thaw, eggs are fertilized using Intracytoplasmic Sperm Injection (ICSI). Lucina’s 2022 ICSI fertilization rate is 89.1%. A high fertilization rate translates directly to more embryos available — which affects how much weight any single PGT-A result carries.
• Embryo development to blastocyst. Day-5 blastocysts have higher implantation potential than day-3 embryos. An egg bank’s ability to reliably produce blastocysts from its donor cohorts is a strong predictor of what you’ll have to work with going into a transfer.
• Uterine receptivity. The recipient’s uterine environment plays a significant role. Endometrial preparation protocols, transfer timing, and addressing any structural uterine issues all contribute to implantation outcomes independently of embryo chromosomal status.
• Donor age and screening. All of Lucina’s donors are between 19 and 31, each passing extensive medical and genetic screening. Donor age at retrieval is one of the strongest predictors of egg quality and chromosomal integrity — which is part of why the baseline for donor egg IVF already looks different from older-egg IVF cycles.

How Lucina’s PGT-A Guarantee Works

If you decide PGT-A is right for your situation, Lucina’s PGT-A Guarantee is designed to protect you financially if things don’t go as planned. It’s one of three components in the Triple Guarantee Program, alongside the Blastocyst Guarantee and the Live Birth Guarantee.

Here’s what it covers: if your initial cohort doesn’t yield a PGT-A-passed embryo, the program provides up to two replacement cohorts. If no eligible embryo is produced after all cohorts, you receive a full refund (excluding shipping). The program costs $25,000 and includes one PGT-A-passed blastocyst per cohort.

The guarantee is structured around a specific outcome — a chromosomally normal embryo ready for transfer — which makes it a meaningful protection for intended parents who have chosen PGT-A as part of their plan. It doesn’t guarantee pregnancy, but it does guarantee that your financial commitment is protected if the testing itself doesn’t produce what you need to move forward.

Read more about donor egg success and guarantee programs to understand how all three tiers work and which one fits your situation. If you want to talk through whether the PGT-A Guarantee makes sense for your cycle specifically, our team is available to walk you through it.

Questions Worth Bringing to Your Care Team

Whether you’re leaning toward PGT-A or weighing it carefully, these questions will help you have a more informed conversation with your reproductive endocrinologist before your cycle.

• “Based on my history, is there a clinical reason PGT-A would benefit me specifically?” This shifts the conversation from a general recommendation to your actual situation, including any chromosomal conditions, prior transfer history, or medical factors that change the picture.
• “How many blastocysts do you expect from this cohort?” The answer shapes how much weight to give any individual PGT-A result. A smaller embryo pool means each embryo in it matters more.
• “How does your clinic handle mosaic embryo results?” Clinics vary significantly in their approach to mosaics. Knowing the answer upfront helps you understand what the full range of outcomes looks like before you commit to testing.
• “Does my uterine environment or transfer history suggest any factors PGT-A wouldn’t address?” Sometimes implantation failure has more to do with uterine receptivity than embryo chromosomal status. Ruling that in or out before adding PGT-A is worth the conversation.
• “Am I a good candidate for Lucina’s PGT-A Guarantee program?” If your care team does recommend PGT-A, asking about how Lucina’s guarantee program provides financial protection is a practical next step.

Making the Right Decision for Your Cycle

PGT-A with donor eggs isn’t a straightforward yes or no. The research establishes that it’s not necessary for every cycle. For some intended parents, it’s the right addition to their plan, and for others, the foundation of a strong donor egg cycle — young, screened eggs, rigorous vitrification, high fertilization rates — already gives them what they need.

What matters most is that you go into this decision with the full picture: what the test does, what the data shows in donor egg populations, and what your own clinical history adds to that equation. That’s a conversation best had with your reproductive endocrinologist, who knows your specific situation.

If you’re weighing PGT-A donor eggs as part of your plan, Lucina’s donor gallery is a good place to start understanding what’s available. Browse 3,000+ screened donors for free with no upfront cost, and create your account to see full profiles, photos, and medical backgrounds when you’re ready.

Frequently Asked Questions